(24/7 MARKET NEWS) – Cardiff Oncology, Inc. (NASDAQ: CRDF) reported, after yesterday’s market close, positive clinical data with onvansertib monotherapy and combination therapy in our ongoing trials in metastatic pancreatic ductal adenocarcinoma (mPDAC) and small cell lung cancer (SCLC), as well as plans for a mPDAC first-line investigator-initiated trial (IIT) of the combination of onvansertib plus standard-of-care (SoC).
Cardiff Oncology is trading at $1.88, up $0.260 (+16.05%), on 4.35M premarket shares traded.
Its 52-week range is $1.20 to $2.79. Its next key inflection point is $2 and it’s already traded above that this morning when it hit this morning’s $2.34 high.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.